Frontlight ResearchEarly access
CompletedPhase 3
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
Key facts
- Who runs it
- Vanda Pharmaceuticals
- Where
- Birmingham, Boston, Brooklyn, Charlotte, Chattanooga, Chesterfield, Chevy Chase, Chula Vista, Columbus, Edmond, Houston, Huber Heights, La Jolla, Las Vegas, Little Rock, Los Angeles, Louisville, Maitland, Marrero, Morrow, Nashville, Palmetto Bay, Peoria, Philadelphia, Plano, Raleigh, Salt Lake City, San Antonio, Tampa, Tulsa, Wauconda, West Des Moines, and Wichita, United StatesSee the 33 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 979 people enrolled
- Started
- 20 Aug 2019
- Ended
- 21 Feb 2025
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Tradipitant
- Placebo
- Open Label Tradipitant
- Record updated
- 24 September 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Diagnosed with gastroparesis
- Demonstrated delayed gastric emptying
- Presence of moderate to severe nausea
- Body Mass Index (BMI) of ≥18 and ≤40 kg/m2
Who cannot take part
- A positive test for drugs of abuse at the screening or evaluation visits
- Exposure to any investigational medication in the past 60 days
- Gastrectomy, fundoplication, vagotomy, pyloroplasty, bariatric surgery, or gastric stimulation device surgically implanted within the last year
- Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis
Where in United States
- Birmingham, AlabamaHospital not named in the registry
- Boston, MassachusettsHospital not named in the registry
- Brooklyn, New YorkHospital not named in the registry
- Charlotte, North CarolinaHospital not named in the registry
- Chattanooga, TennesseeHospital not named in the registry
- Chesterfield, MissouriHospital not named in the registry
- Chevy Chase, MarylandHospital not named in the registry
- Chula Vista, CaliforniaHospital not named in the registry
- Columbus, OhioHospital not named in the registry
- Edmond, OklahomaHospital not named in the registry
- Houston, TexasHospital not named in the registry
- Huber Heights, OhioHospital not named in the registry
- La Jolla, CaliforniaHospital not named in the registry
- Las Vegas, NevadaHospital not named in the registry
- Little Rock, ArkansasHospital not named in the registry
- Los Angeles, CaliforniaHospital not named in the registry
- Louisville, KentuckyHospital not named in the registry
- Maitland, FloridaHospital not named in the registry
- Marrero, LouisianaHospital not named in the registry
- Morrow, GeorgiaHospital not named in the registry
- Nashville, TennesseeHospital not named in the registry
- Palmetto Bay, FloridaHospital not named in the registry
- Peoria, ArizonaHospital not named in the registry
- Philadelphia, PennsylvaniaHospital not named in the registry
- Plano, TexasHospital not named in the registry
- Raleigh, North CarolinaHospital not named in the registry
- Salt Lake City, UtahHospital not named in the registry
- San Antonio, TexasHospital not named in the registry
- Tampa, FloridaHospital not named in the registry
- Tulsa, OklahomaHospital not named in the registry
- Wauconda, IllinoisHospital not named in the registry
- West Des Moines, IowaHospital not named in the registry
- Wichita, KansasHospital not named in the registry
About the trial
What the trial wants to find out
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
The 3 groups in the trial
- TradipitantTreatment being tested
Oral Capsule
- PlaceboPlacebo, for comparison
Oral Capsule
- Open Label TradipitantTreatment being tested
Oral Capsule
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis
- Record updated
- 24 September 2026